Oculopharyngeal muscular dystrophy?(OPMD) is a rare genetic muscle disorder with onset during adulthood most often between 40 and 60 years of age. OPMD is characterized by slowly progressive muscle disease (myopathy) affecting the muscles of the upper eyelids and the throat.
This report contains market size and forecasts of Oculopharyngeal Muscular Dystrophy (OPMD) in global, including the following market information:
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Oculopharyngeal Muscular Dystrophy (OPMD) companies in 2021 (%)
The global Oculopharyngeal Muscular Dystrophy (OPMD) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Tablets Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Oculopharyngeal Muscular Dystrophy (OPMD) include Benitec Biopharma Inc., Bioblast Pharma, BioMarin, PTC Therapeutics, NS Pharma, Nobelpharma Co., Ltd, Santhera Pharmaceuticals, Pfizer Inc. and Marathon Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Oculopharyngeal Muscular Dystrophy (OPMD) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market, By Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Segment Percentages, By Type, 2021 (%)
Tablets
Capsules
Injectable
Other
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market, By Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Segment Percentages, By Application, 2021 (%)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Oculopharyngeal Muscular Dystrophy (OPMD) revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Oculopharyngeal Muscular Dystrophy (OPMD) revenues share in global market, 2021 (%)
Key companies Oculopharyngeal Muscular Dystrophy (OPMD) sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Oculopharyngeal Muscular Dystrophy (OPMD) sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Benitec Biopharma Inc.
Bioblast Pharma
BioMarin
PTC Therapeutics
NS Pharma
Nobelpharma Co., Ltd
Santhera Pharmaceuticals
Pfizer Inc.
Marathon Pharmaceuticals
Fibrogen
Bristol-Myers Squibb
Sarepta Therapeutics
GSK

1 Introduction to Research & Analysis Reports
1.1 Oculopharyngeal Muscular Dystrophy (OPMD) Market Definition
1.2 Market Segments
1.2.1 Market By Type
1.2.2 Market By Application
1.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Overall Market Size
2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size: 2021 VS 2028
2.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales: 2017-2028
3 Company Landscape
3.1 Top Oculopharyngeal Muscular Dystrophy (OPMD) Players in Global Market
3.2 Top Global Oculopharyngeal Muscular Dystrophy (OPMD) Companies Ranked by Revenue
3.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Companies
3.4 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Companies
3.5 Global Oculopharyngeal Muscular Dystrophy (OPMD) Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Oculopharyngeal Muscular Dystrophy (OPMD) Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Product Type
3.8 Tier 1, Tier 2 and Tier 3 Oculopharyngeal Muscular Dystrophy (OPMD) Players in Global Market
3.8.1 List of Global Tier 1 Oculopharyngeal Muscular Dystrophy (OPMD) Companies
3.8.2 List of Global Tier 2 and Tier 3 Oculopharyngeal Muscular Dystrophy (OPMD) Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size Markets, 2021 & 2028
4.1.2 Tablets
4.1.3 Capsules
4.1.4 Injectable
4.1.5 Other
4.2 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue & Forecasts
4.2.1 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2022
4.2.2 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2023-2028
4.2.3 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
4.3 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales & Forecasts
4.3.1 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2022
4.3.2 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2023-2028
4.3.3 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
4.4 By Type - Global Oculopharyngeal Muscular Dystrophy (OPMD) Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
5.1 Overview
5.1.1 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2021 & 2028
5.1.2 Hospital Pharmacies
5.1.3 Retail Pharmacies
5.1.4 Online Pharmacies
5.2 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue & Forecasts
5.2.1 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2022
5.2.2 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2023-2028
5.2.3 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
5.3 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales & Forecasts
5.3.1 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2022
5.3.2 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2023-2028
5.3.3 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
5.4 By Application - Global Oculopharyngeal Muscular Dystrophy (OPMD) Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
6.1 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2021 & 2028
6.2 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue & Forecasts
6.2.1 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2022
6.2.2 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2023-2028
6.2.3 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share, 2017-2028
6.3 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales & Forecasts
6.3.1 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2022
6.3.2 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2023-2028
6.3.3 By Region - Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2028
6.4.2 By Country - North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2028
6.4.3 US Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.4.4 Canada Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.4.5 Mexico Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2028
6.5.2 By Country - Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2028
6.5.3 Germany Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.5.4 France Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.5.5 U.K. Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.5.6 Italy Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.5.7 Russia Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.5.8 Nordic Countries Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.5.9 Benelux Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2028
6.6.2 By Region - Asia Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2028
6.6.3 China Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.6.4 Japan Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.6.5 South Korea Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.6.6 Southeast Asia Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.6.7 India Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2028
6.7.2 By Country - South America Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2028
6.7.3 Brazil Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.7.4 Argentina Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales, 2017-2028
6.8.3 Turkey Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.8.4 Israel Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.8.5 Saudi Arabia Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
6.8.6 UAE Oculopharyngeal Muscular Dystrophy (OPMD) Market Size, 2017-2028
7 Manufacturers & Brands Profiles
7.1 Benitec Biopharma Inc.
7.1.1 Benitec Biopharma Inc. Corporate Summary
7.1.2 Benitec Biopharma Inc. Business Overview
7.1.3 Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.1.4 Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.1.5 Benitec Biopharma Inc. Key News
7.2 Bioblast Pharma
7.2.1 Bioblast Pharma Corporate Summary
7.2.2 Bioblast Pharma Business Overview
7.2.3 Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.2.4 Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.2.5 Bioblast Pharma Key News
7.3 BioMarin
7.3.1 BioMarin Corporate Summary
7.3.2 BioMarin Business Overview
7.3.3 BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.3.4 BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.3.5 BioMarin Key News
7.4 PTC Therapeutics
7.4.1 PTC Therapeutics Corporate Summary
7.4.2 PTC Therapeutics Business Overview
7.4.3 PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.4.4 PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.4.5 PTC Therapeutics Key News
7.5 NS Pharma
7.5.1 NS Pharma Corporate Summary
7.5.2 NS Pharma Business Overview
7.5.3 NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.5.4 NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.5.5 NS Pharma Key News
7.6 Nobelpharma Co., Ltd
7.6.1 Nobelpharma Co., Ltd Corporate Summary
7.6.2 Nobelpharma Co., Ltd Business Overview
7.6.3 Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.6.4 Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.6.5 Nobelpharma Co., Ltd Key News
7.7 Santhera Pharmaceuticals
7.7.1 Santhera Pharmaceuticals Corporate Summary
7.7.2 Santhera Pharmaceuticals Business Overview
7.7.3 Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.7.4 Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.7.5 Santhera Pharmaceuticals Key News
7.8 Pfizer Inc.
7.8.1 Pfizer Inc. Corporate Summary
7.8.2 Pfizer Inc. Business Overview
7.8.3 Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.8.4 Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.8.5 Pfizer Inc. Key News
7.9 Marathon Pharmaceuticals
7.9.1 Marathon Pharmaceuticals Corporate Summary
7.9.2 Marathon Pharmaceuticals Business Overview
7.9.3 Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.9.4 Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.9.5 Marathon Pharmaceuticals Key News
7.10 Fibrogen
7.10.1 Fibrogen Corporate Summary
7.10.2 Fibrogen Business Overview
7.10.3 Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.10.4 Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.10.5 Fibrogen Key News
7.11 Bristol-Myers Squibb
7.11.1 Bristol-Myers Squibb Corporate Summary
7.11.2 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Business Overview
7.11.3 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.11.4 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.11.5 Bristol-Myers Squibb Key News
7.12 Sarepta Therapeutics
7.12.1 Sarepta Therapeutics Corporate Summary
7.12.2 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Business Overview
7.12.3 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.12.4 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.12.5 Sarepta Therapeutics Key News
7.13 GSK
7.13.1 GSK Corporate Summary
7.13.2 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Business Overview
7.13.3 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Major Product Offerings
7.13.4 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Revenue in Global (2017-2022)
7.13.5 GSK Key News
8 Global Oculopharyngeal Muscular Dystrophy (OPMD) Production Capacity, Analysis
8.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Production Capacity, 2017-2028
8.2 Oculopharyngeal Muscular Dystrophy (OPMD) Production Capacity of Key Manufacturers in Global Market
8.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Oculopharyngeal Muscular Dystrophy (OPMD) Supply Chain Analysis
10.1 Oculopharyngeal Muscular Dystrophy (OPMD) Industry Value Chain
10.2 Oculopharyngeal Muscular Dystrophy (OPMD) Upstream Market
10.3 Oculopharyngeal Muscular Dystrophy (OPMD) Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Oculopharyngeal Muscular Dystrophy (OPMD) Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer